Explore Chonluten (T-34) dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. Real-world bronchopulmonary peptide bioregulator mixing data.
Chonluten (T-34) is a short tripeptide bronchopulmonary bioregulator — Glu-Asp-Gly (EDG) — from the Khavinson family of organ-specific "cytomax" peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology, studied in Russian-language literature for its proposed regulatory effect on lung and bronchial epithelial tissue. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when setting up a Chonluten reconstitution protocol, distinct from the larger growth-factor and metabolic peptides tracked elsewhere on WPA.
Chonluten belongs to the Khavinson short-peptide bioregulators — a family of two-to-four-amino-acid peptides developed over several decades by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, each proposed to act on a single organ system. Chonluten is the bronchopulmonary (lung) member of that family: the tripeptide Glu-Asp-Gly (EDG), sometimes catalogued under the laboratory designation T-34. The Khavinson framework hypothesizes that these ultra-short peptides interact directly with DNA promoter regions to modulate tissue-specific gene expression, and Chonluten specifically is positioned in the Russian-language literature as a regulator of bronchial and alveolar epithelial cell function. g. the oral capsule lineage) and the synthetic short-peptide "cytogen" forms such as the injectable EDG tripeptide tracked here.
Chonluten is a synthetic Glu-Asp-Gly (EDG) tripeptide from the Khavinson program, sourced for bronchial/pulmonary-tissue and aging research. It ships as a lyophilized powder you reconstitute before use, so the real vendor difference is what the certificate of analysis (COA) shows.
In the Khavinson framework, Chonluten is proposed to act through direct binding to gene-promoter DNA in bronchial epithelial and pulmonary cells, selectively modulating transcription of genes involved in mucosal repair, ciliated-cell turnover, and local antioxidant defense. This proposed direct-DNA-binding mechanism is unconventional and has not been independently characterised outside the Khavinson group.
Russian single-site studies have reported Chonluten as an adjunct in chronic bronchopulmonary pathology — chronic bronchitis, COPD, and post-pneumonia rehabilitation in elderly patients — with reported improvements in symptom scores and pulmonary-function tests versus standard care. These studies are not blinded or placebo-controlled, and no Western Phase 2 or 3 trial has been registered.
Chonluten has a reported half-life of ~few hours (bioregulator estimate), and the dose intervals researchers model most often fall around once daily. Short-lived in plasma with daily dosing, so there is no real buildup. As with other bioregulators, a course's effect is thought to persist afterward. It is catalogued under Recovery Peptides on WPA.
6 Chonluten reconstitution calculations have been logged by the WPA community. The most common dose entered is 2mg (4 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (5 sessions).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.